AXIOS August 28, 2024
Adriel Bettelheim

Pfizer on Tuesday became the latest major drugmaker to sell medicine directly to consumers, launching a digital platform that’s initially directed at people with migraines and respiratory ailments, including COVID-19.

Why it matters: The move puts Pfizer in competition with Eli Lilly, which in January launched its own D2C platform to provide prescriptions for conditions like obesity, migraines, and diabetes.

  • The new portal could stir up more business for Pfizer drugs, though the company said patients won’t be steered to its products and that decisions will remain with physicians.

Driving the news: The PfizerForAll platform leverages partnerships with telehealth provider UpScriptHealth, online pharmacy Alto Pharmacy, and the grocery delivery service Instacart.

  • It offers $35 virtual appointments with...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Digital Health, Patient / Consumer, Pharma, Pharma / Biotech, Technology, Telehealth
Related Articles:
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights
Putting Patients First by Extending the Reach of World-Class Care
Biotech startups are built on venture capital. Track funding rounds here.
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
What might a Trump administration mean for the Biosecure Act?

Share This Article